| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
SIGA Technologies Inc.$3.59
+0.09 (+2.57%)
D 30Pipeline Score Overvalued Pharma · Commercial
Market Cap
335.67 M
EPS
0.28
P/E Ratio
16.62 $
Value Trade
1.40 M
SEC Financials
Q1 2026Dilution Risk
Revenue
6.24 M
R&D Expenses
3.95 M
Operating CF
-8.66 M
Total Assets
219.39 M
Total Liabilities
67.77 M
Equity
151.62 M
D/E Ratio
12,345
10.9 %
Week
5.41 %
1 Month
-30.56 %
3 Month
-18.32 %
6 Month
-33.71 %
5 Year
-6.4 %
All Time
Cash Data
Cash Position
145.56 M
Monthly Burn
2.89 M
Runway
48.5 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
627.49 K
52 Week Range
4.10 - 9.62
% held by Insiders
42.83 %
% held by Institutions
48.19 %
Enterprise Value
190.74 M
Total Shares
71.62 M
Short %
8.58 %
Float Shares
40.39 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for SIGA Technologies Inc.
281Total events
1Upcoming
62Tier-1 (high impact)
2004 – 2026Coverage
Upcoming catalysts 1
Event history 280
Q3 2026
▲Product LaunchTPOXX®ApprovedPost-Market
Expected delivery of oral and IV TPOXX to U.S. Government and international customer
orthopoxvirus infectionssource ↗
May 7, 2026
◆Quarterly UpdateCorporate
First-quarter 2026 financial results release and business update call
Q2 2026
◆Timing GuidanceTPOXX®ApprovedPresentation
Expects to deliver >$35M of oral and IV TPOXX to U.S. Government and international customer in Q2-Q3 2026
orthopoxvirus (smallpox)source ↗
Q2 2026
▲Product LaunchTPOXX®ApprovedPost-Market
Expected delivery of oral and IV TPOXX to U.S. Government and international customer
orthopoxvirus infectionssource ↗
Mar 10, 2026
Jan 2026
▲Partnership / LicenseTPOXX®ApprovedCorporate
Received $13 million procurement order from Asia Pacific customer for oral TPOXX
orthopoxvirus infectionsource ↗
Q3 2025
Apr 8, 2025
Drug Pipeline Intelligence
D30
Pipeline Score $96M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.3x
rNPV / MCap Top 34%
Micro Cap (rank 602 of 911)
Percentile RankSIGA Technologies Inc. faces pipeline headwinds (30/100), with $241M risk-adjusted pipeline value, led by ST-246 in Orthopoxviral Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ST-246 Small molecule | Orthopoxviral Disease | Phase 2 | NCT00907803 | 21% | $171M | COMPLETED | 107 | - | - | Jan 1, 2010 | - | Sep 21, 2010 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Tecovirimat | mpox | — | 2024-12-10 | did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo Read More | Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate Read More | |
Tecovirimat | mpox | — | 2024-12-10 | did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo Read More | Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate Read More | |
Tecovirimat | mpox | — | 2024-12-10 | did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo Read More | Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SIGA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SIGA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SIGASIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update
SIGA Technologies, Inc. reported its financial results for Q1 2026, highlighting expectations to deliver over $35 million of TPOXX to various customers. The CEO emphasized the company's strategy to secure new contracts to enhance business growth. However, SIGA faces several risks, including potential delays in contract performance and challenges in the international market.
Read more →SIGASIGA Reports Financial Results for Three Months Ended
SIGA Technologies, Inc. reported its financial results for the three months ending March 31, 2026. The company expects to deliver more than $35 million of TPOXX in the upcoming quarters, focusing on securing new procurement contracts. Despite these optimistic projections, SIGA experienced a significant financial downturn, reporting a net loss of $3.5 million compared to $0.4 million the year prior, alongside a drop in product sales. The company continues to highlight its commitment to serving both domestic and international markets as a partner in biodefense.
Read more →SIGASIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results
SIGA Technologies, Inc. will host a business update call on May 7, 2026, to discuss its first-quarter financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. Participants can join via phone or webcast, with a replay available for two weeks. SIGA focuses on developing medicines for infectious diseases.
Read more →SIGASIGA Reports Financial Results for Three and Twelve Months Ended
SIGA Technologies, Inc. has reported its financial results for the year ended December 31, 2025. The company generated $88 million in product revenues but experienced a net loss of $5.4 million for the fourth quarter. Despite the challenges, SIGA secured $27 million in government funding and received a procurement order worth $13 million for its oral TPOXX product. The company aims to strengthen its position as a reliable partner to governments for future revenues.
Read more →SIGA▼ -5%on this news
SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results
SIGA Technologies, Inc. has announced a business update call scheduled for March 10, 2026, at 4:30 PM ET. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire, providing insights into the company's 2025 financial results. A live webcast will be available, along with a replay for two weeks afterward.
Read more →SIGA▼ -20%on this news
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025
SIGA Technologies, Inc. reported strong financial results for the first nine months of 2025, achieving $86 million in product revenues and $33 million in pre-tax operating income. The company is focused on expanding its partnerships with government entities to secure future procurement contracts. A conference call is scheduled to discuss their business updates.
Read more →SIGASIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results
SIGA Technologies, Inc. will host a business update call on November 6, 2025, at 4:30 PM ET to discuss its third-quarter results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. Participants can join via phone or a live webcast, with a replay available afterward. SIGA is known for its antiviral product TPOXX, aimed at treating smallpox and other orthopoxvirus infections.
Read more →SIGASIGA Reports Financial Results for Three and Six Months Ended
SIGA Technologies, Inc. reported robust financial results for the second quarter and six months ending June 30, 2025. The company generated substantial revenues from its product, TPOXX, totaling approximately $79.1 million, alongside additional development funding from BARDA totaling $27 million. These results underscore SIGA's strong business model and the increasing demand for TPOXX, particularly for uses in treating smallpox. Furthermore, SIGA declared a special dividend, reflecting positive cash flow and shareholder value.
Read more →SIGA▲ +11.1%on this news
SIGA Declares Special Cash Dividend of $0.60 Per Share
SIGA Technologies, Inc. has announced a special cash dividend of $0.60 per share, marking the fourth consecutive year of such dividends. The dividend is consistent with the previous year's amount and will be payable on May 15, 2025, to shareholders of record by April 29, 2025. CEO Diem Nguyen highlighted the company's strong financial position and commitment to shareholder value.
Read more →SIGASIGA Appoints Retired General John M. Keane to its Board of Directors
SIGA Technologies has appointed Retired General John M. Keane to its Board of Directors. General Keane brings extensive military and national security experience, which SIGA believes will enhance its efforts in biodefense. His insights are expected to be valuable as the company aims to expand its antiviral reach and collaborate with government stakeholders.
Read more →SIGA▼ -6.8%on this news
Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate
SIGA's interim results from the STOMP clinical trial revealed that their antiviral treatment tecovirimat failed to improve lesion resolution in patients with mild to moderate mpox compared to a placebo. Following these findings, the study's Data Safety and Monitoring Board recommended halting enrollments in both the randomized and open-label arms of the trial. Approximately 75% of participants received treatment after more than five days of symptom onset, which may have affected the outcomes. While the safety profile of tecovirimat appeared similar to placebo, ongoing analysis of primary endpoints remains incomplete.
Read more →SIGASIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
SIGA Technologies is facing a crisis after its lead product, TPOXX®, failed to demonstrate efficacy in clinical trials for Mpox treatment, leading to a nearly 20% plummet in stock prices. The situation worsened with the termination of its Chief Medical Officer, which occurred without explanation, and allegations of misleading investors about the drug's effectiveness surfaced. As a result, shareholder rights firm Hagens Berman is now investigating SIGA for potential violations of U.S. securities laws, as the company's statements regarding TPOXX® may have misled investors.
Read more →SIGASIGA Reports Financial Results for Three and Nine Months Ended
SIGA Technologies reported financial results for the three and nine months ending September 30, 2024, showcasing a significant increase in net income and product sales. The company secured $122 million in orders, including a major contract with BARDA and the Department of Defense. With approximately $146 million in outstanding procurement orders, SIGA anticipates robust revenue growth in the upcoming quarters. However, they face uncertainty with potential contract modifications and market challenges.
Read more →SIGASIGA ALERT: Bragar Eagel & Squire, P.C. is Investigating SIGA Technologies, Inc. on Behalf of SIGA Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating SIGA Technologies, Inc. on behalf of its stockholders due to potential violations of federal securities laws. This follows the termination of the Chief Medical Officer, Dr. Jay Varma, which led to a significant drop in stock price. Additionally, a secretly recorded video surfaced, suggesting attempts to manipulate public perception of the TPOXX treatment for Monkeypox, resulting in further financial losses for investors.
Read more →SIGA▼ -19.6%on this news
Topline Results from PALM 007 Study of SIGA'S Tecovirimat in Treatment of Mpox Released Preliminary analysis shows the study did not reach statistical significance on its primary endpoint of tecovirimat being superior to
The PALM 007 study results showed that SIGA's tecovirimat did not achieve statistical significance in improving lesion resolution for mpox patients. However, the drug demonstrated potential benefits for severely ill patients who received treatment early. The safety profile of tecovirimat was comparable to placebo. Further analysis is necessary to refine the understanding of treatment effectiveness and to plan future trials.
Read more →SIGASIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX Exercise of Procurement Option under Current Contract Reflects Continuing Action to Enhance Orthopoxvirus Preparedness NEW YORK (GLOBE NEWSW
SIGA Technologies, Inc. announced a $113 million procurement order from the U.S. Department of Health and Human Services for oral TPOXX treatment courses. This order aims to enhance national preparedness against orthopoxvirus threats and reflects SIGA's ongoing commitment to public health. The announcement highlights SIGA's leadership in the development of countermeasures against serious infectious diseases. However, the company faces various risks related to contract fulfillment and market competition.
Read more →SIGA▲ +6.1%on this news· ran to +18% by day 3
SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results
SIGA Technologies, Inc. plans to host a conference call on May 7, 2024, to discuss a business update following its first-quarter financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire and will be accessible via webcast. SIGA continues to focus on health security products, including its antiviral drug TPOXX, approved for treating smallpox and other orthopoxvirus-related conditions. The company emphasizes its role in biodefense and preparedness against potential health threats.
Read more →SIGASIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results
SIGA Technologies, Inc. announced a business update call scheduled for March 12, 2024, where management will provide insights following the release of its fourth-quarter and full-year 2023 financial results. The call will feature CEO Dr. Diem Nguyen and CFO Daniel Luckshire. SIGA's lead product, TPOXX, has received various regulatory approvals, reflecting its importance in the biodefense market. However, the company also faces risks related to government contracts and market challenges.
Read more →SIGASIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer
SIGA Technologies, Inc. announced the appointment of Diem Nguyen, Ph.D., as the new Chief Executive Officer, effective January 27, 2024. Dr. Nguyen, who has a strong background in biopharmaceutical leadership, replaces retiring CEO Dr. Phil Gomez. The incorporation of Dr. Nguyen is viewed as a strategic move to enhance SIGA's capabilities in securing partnerships for global health security and advancing antiviral therapies. Her previous experience at leading companies like Pfizer suggests a promising outlook for SIGA's future initiatives.
Read more →SIGASIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results
SIGA Technologies, Inc. has announced a business update call scheduled for November 7th, 2023, at 4:30 P.M. ET, to discuss their third-quarter financial results. Key executives including the CEO, Chief Medical Officer, and Chief Financial Officer will participate in the call. Investors can access the call through a dedicated phone line or via webcast on the company's website. This call reflects SIGA's commitment to maintaining open communication with stakeholders about its performance and initiatives.
Read more →SIGASIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer
SIGA Technologies has appointed Dr. Jay K. Varma as its Executive Vice President and Chief Medical Officer, a role aimed at enhancing the company's public health initiatives. Dr. Varma, who has experience in managing infectious disease responses, will lead medical affairs and collaborate with various public health organizations. His appointment aligns with SIGA's objective to bolster awareness and preparation for outbreaks of smallpox and MPOX. The company continues to position itself as a critical player in health security, particularly with its lead product, TPOXX.
Read more →SIGA▲ +8.6%on this news
SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOX
SIGA Technologies announced the U.S. government's procurement orders totaling approximately $138 million for its TPOXX products, which include both oral and intravenous formulations. The orders, reflecting the government's commitment to smallpox preparedness, consist of about $113 million for oral TPOXX and $25 million for IV TPOXX. SIGA plans to fully deliver the oral TPOXX by the end of 2023 and initiate deliveries for IV TPOXX in 2024. The announcement highlights SIGA's ability to meet rising global demand for antiviral treatments and strengthens the company's position in the health security market.
Read more →SIGASIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results
SIGA Technologies, Inc. has announced a business update call scheduled for August 8, 2023, following the release of their second quarter financial results. The call will feature key executives, including the CEO and CFO, who will discuss the company's performance and future outlook. SIGA is known for its antiviral drug TPOXX, which has garnered significant regulatory approvals. The event aims to inform stakeholders about the company's direction in the health security market.
Read more →SIGASIGA Declares Special Cash Dividend of $0.45 Per Share
SIGA Technologies, Inc. announced a special cash dividend of $0.45 per share, which is set to be paid on June 1, 2023, to shareholders on record by May 16. This decision reflects the company's strong financial performance and resources, as stated by the CEO. SIGA is recognized for its role in the health security market, particularly with its product TPOXX, approved for smallpox treatment.
Read more →SIGASIGA Technologies to Host Business Update Call on May 4th, 2023 Following Release of First Quarter 2023 Financial Results
SIGA Technologies has announced a forthcoming business update call scheduled for May 4, 2023, at 4:30 PM ET. The call will include management members such as CEO Dr. Phil Gomez and CFO Daniel Luckshire, who will discuss the first quarter 2023 financial results. This event highlights SIGA's ongoing focus in the health security market, particularly regarding their lead product, TPOXX. With substantial regulatory feedback received, the company's transparency in financial communication signals an optimistic outlook for its shareholders.
Read more →SIGASIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results
SIGA Technologies, Inc. has announced a business update call scheduled for March 2, 2023, following its release of fourth quarter and full-year 2022 financial results. The call will be led by Dr. Phil Gomez, CEO, and Daniel Luckshire, CFO, reflecting the company's ongoing engagement with investors. SIGA is known for its antiviral drug TPOXX, which is approved for the treatment of smallpox and has also received attention for potential uses against other infections. The company emphasizes its commitment to health security and biodefense challenges.
Read more →SIGA▼ -9.6%on this news
SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023 SIGA Board of Directors has initiated search for new CEO; Dr. Gomez expected to remain in position as CEO until the search is completed to support
SIGA Technologies, Inc. has announced the planned retirement of its CEO, Phil Gomez, who will remain in his position until a successor is found. The Board of Directors has initiated a search for a new CEO, aiming for a smooth transition to maintain the company's trajectory. Gomez has led SIGA since 2016, overseeing growth and responding to global health crises. His departure is framed as a strategic opportunity for new leadership within the company.
Read more →SIGASIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 3rd, 20
Read more →SIGASIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Department of Defense (DoD) awarded a new contract to SIGA for the procuremen
Read more →SIGASIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX - IV TPOXX is an Important Option for Those Unable to Swallow - - Option to Fund Post-Marketing Field Study for IV TPO
SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX Important Option for Those Unable to Swallow - Option to Fund Post-Marketing Field Study for IV TPOXX also Exercised - NEW YORK, Aug. 9, 2022 (GLOBE NEWSWIRE) -- SIGA Technolo
Read more →SIGA▲ +24.9%on this news
SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 4th, 2022
Read more →SIGASIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX (Tecovirimat) - Approximately $26 Million of Orders Received from Canada under Existing Procurement Contracts - - Approximately
SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX (Tecovirimat) - Approximately $26 Million of Orders Received from Canada under Existing Procurement Contracts - - Approximately $2 Million of Orders Received from Two New Jurisdictions
Read more →SIGA▼ -8.6%on this newsshared move
SIGA Technologies Receives Approval from UK for Tecovirimat
NEW YORK, July 08, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United Kingdom has approved SIGA’s oral tecovirimat (known in the U.S. as oral TPOX
Read more →SIGASIGA Declares Special Dividend of $0.45 Per Share
SIGA Declares Special Dividend of $0.45 Per Share May 5, 2022, 7:30 am ET NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special dividend of $0.45 per share on the com
Read more →SIGASIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 5th, 2022.
Read more →SIGASIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 3rd, 2022.
Read more →SIGA▼ -5.2%on this news
SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, announced today that it will be participating in Edison Group’s Open House Event, scheduled to take place vi
Read more →SIGASIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the European Medicines Agency (EMA) approved SIGA’s Marketing Authorisation Application
Read more →SIGASIGA Reports Financial Results for Third Quarter and Nine Months Ended
SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021 Up to Approximately $113 Million of Oral TPOXX Targeted for Delivery to the U.S. Government in the Fourth Quarter - - Approximately $13 Million of International Sales for the First Nine Mo
Read more →SIGASIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 4th, 20
Read more →SIGASIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that Dr. Phil Gomez, the Company’s Chief Executive Officer, will be a speaker at the NCT USA conference on September 8, in Baltim
Read more →SIGASIGA Technologies to Host Business Update Call on August 5th, 2021 Following Release of Second Quarter 2021 Financial Results
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 5th, 2021
Read more →SIGASIGA Technologies to Host Business Update Call on May 6th, 2021 Following Release of First Quarter 2021 Financial Results
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 6, 2021. Pa
Read more →SIGASIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results
NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30
Read more →SIGASIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX Second Contract by a Canadian Governmental Agency for the Procurement of Oral TPOXX
SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral Second Contract by a Canadian Governmental Agency for the Procurement of Oral TPOXX NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage p
Read more →SIGASIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, Chief Scientific Officer, will participate in a panel discussion at t
Read more →SIGASIGA Technologies to Host Business Update Call on November 5, 2020 Following Release of Third Quarter Financial Results
NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30
Read more →SIGASIGA Technologies, Inc. Reports Financial Results for Three and Six Months Ended
SIGA Technologies, Inc. Reports Financial Results for Three and Six Months Ended June 30, 2020 - Second Quarter includes Deliveries to SNS and First International - Corporate Update Conference Call Today at 4:30 PM ET - August 6, 2020, 4:05 pm ET NEW YORK -- SIGA Technologies
Read more →SIGASIGA Technologies to Host Business Update Call on August 6, 2020 Following Release of Second Quarter Financial Results
NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30
Read more →SIGASIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United States Department of Defense (DoD), via the Joint Program Executive Office f
Read more →SIGASIGA Technologies Announces First International Delivery of Oral TPOXX
- 2,500 Courses Delivered to the Canadian Department of National Defence - NEW YORK, June 01, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced its first intern
Read more →SIGASIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020 - Company Recently Announced Exercise of Contract Options Totaling $101.3 million - - Corporate Update Conference Call Today at 4:30
SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020 - Company Recently Announced Exercise of Contract Options Totaling $101.3 million - - Corporate Update Conference Call Today at 4:30 PM ET - May 6, 2020, 4:05 pm ET NEW YORK -- SIGA Technologies,
Read more →SIGASIGA Technologies to Host Business Update Call on May 6, 2020 after Release of First Quarter Financial Results
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:3
Read more →SIGASIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the Procurement of Oral TPOXX Deliveries to Maintain National Security Expected to Start in Second Quarter 2020
SIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the Procurement of Oral Deliveries to Maintain National Security Expected to Start in Second Quarter 2020 NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutica
Read more →SIGASIGA Technologies, Inc. Reports Financial Results for Fiscal Year 2019 - Announces Expectations for Product Delivery to BARDA - - Announces $50 Million Share Repurchase Program - - Corporate Update Conference Call Today
SIGA Technologies, Inc. Reports Financial Results for Fiscal Year 2019 - Announces Expectations for Product Delivery to BARDA - - Announces $50 Million Share Repurchase Program - - Corporate Update Conference Call Today at 4:30 PM ET - March 5, 2020, 4:05 pm ET NEW YORK -- S
Read more →SIGASIGA Technologies CEO to Speak at NCT Asia Conference on October 23, 2019
NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventiona
Read more →SIGASIGA Technologies CSO to Speak at The 13th CBRNe Protection Symposium on September 25, 2019
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis E. Hruby, the Company’s Chief Scientific Officer, will be a speaker at the
Read more →SIGASIGA Technologies CEO to Speak at NCT Europe on June 27, 2019
NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventiona
Read more →SIGASIGA Technologies to Host Business Update Webcast on June 18, 2019
NEW YORK, June 11, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30
Read more →SIGASIGA Announces TPOXX Promotion Agreement with Meridian Medical Technologies, Inc. (A Pfizer Company) for International Markets
SIGA Announces TPOXX Promotion Agreement with Meridian Medical Technologies, Inc. (A Pfizer Company) for International June 3, 2019, 7:30 am ET NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security m
Read more →SIGASIGA Announces Exercise of Option for the Purchase of Raw Materials for Oral TPOXX Manufacturing Totaling $11 Million Raw Materials expected to be used to Support Manufacture of 363,070 Courses of Oral TPOXX
SIGA Announces Exercise of Option for the Purchase of Raw Materials for Oral TPOXX Manufacturing Totaling $11 Million Raw Materials expected to be used to Support Manufacture of 363,070 Courses of Oral TPOXX NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commerci
Read more →SIGASIGA Announces Priority Review Voucher Transaction Totaling $80 Million
SIGA Announces Priority Review Voucher Transaction Totaling $80 Million November 1, 2018, 7:30am ET NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered i
Read more →SIGASIGA Technologies to Host Business Update Webcast on September 27, 2018
NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:3
Read more →SIGASIGA Technologies to Ring the Nasdaq Opening Bell on Friday, September 14, 2018
NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that that management will be ringing the Nasdaq Stock Market Opening Bell on Friday, Septem
Read more →SIGASIGA Technologies Awarded BARDA Contract for TPOXX - Contract Valued at Up to $629 Million - - Contract Includes Delivery of Oral and Intravenous (IV) Formulations of TPOXX; Development of IV TPOXX; Post-marketing Activi
SIGA Technologies Awarded BARDA Contract for TPOXX - Contract Valued at Up to $629 Million - - Contract Includes Delivery of Oral and Intravenous (IV) Formulations of TPOXX; Development of IV TPOXX; Post-marketing Activities - NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ
Read more →SIGASIGA Technologies Stock Trading Halted Today; FDA Advisory Committee is Scheduled to Review New Drug Application of TPOXX
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that Nasdaq has halted trading of
Read more →SIGASIGA Technologies Announces Favorable Outcome of Advisory Committee In Support of TPOXX
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced a favorable outcome of the U.S. Fo
Read more →SIGASIGA Technologies Announces Relisting on Nasdaq
NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that The Nasdaq Stock Market LLC
Read more →SIGASIGA Technologies Announces FDA Accepts NDA and Grants Priority Review for Oral TPOXX to Treat Smallpox
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that the U.S. Food and Drug Admi
Read more →SIGASIGA Technologies Announces FDA Submission of its New Drug Application for oral TPOXX (tecovirimat) to Treat Smallpox
– Company requests Priority Review of TPOXX NDA – – If approved, would be the first treatment for deadly smallpox – NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a health security company specializing in the development and commercia
Read more →SIGAUNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK x : In re : Chapter 11 Case No. : SIGA TECHNOLOGIES, INC., : 14-12623 (SHL) : Reorganized Debtor. : : x FINAL DECREE PURSUANT TO 11 U.S.C. 350(a) AND FED. R. B
UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK x : In re : Chapter 11 Case No. : SIGA TECHNOLOGIES, INC., : 14-12623 (SHL) : Reorganized Debtor. : : x FINAL DECREE PURSUANT TO 11 U.S.C. 350(a) AND FED. R. BANKR. P. 3022 CLOSING CHAPTER 11 CASE OF
Read more →SIGASIGA Announces Commencement of Rights Offering NEW YORK, NY --(BUSINESS WIRE) -- SIGA Technologies, Inc. ("SIGA" or the "Company") (OTCMKTS:SIGA) today announced that it has commenced a rights offering (the "Rights Offer
SIGA Announces Commencement of Rights Offering NEW YORK, NY--(BUSINESS WIRE) -- SIGA Technologies, Inc. ("SIGA" or the "Company") (OTCMKTS:SIGA) today announced that it has commenced a rights offering (the "Rights Offering") for approximate gross proceeds of $35,000,000. As part
Read more →SIGAStephen Karotkin WEIL, GOTSHAL & MANGES LLP 767 Fifth Avenue New York, New York 10153 Telephone: (212) 310-8000 Facsimile: (212) 310-8007 Attorneys for Reorganized Debtor UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT
WEIL, GOTSHAL & MANGES LLP New York, New York 10153 Attorneys for Reorganized Debtor UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK x : In re : Chapter 11 Case No. : SIGA TECHNOLOGIES, INC., : 14-12623 (SHL) : Reorganized Debtor. : : x MOTION OF R
Read more →SIGASIGA Announces Data Safety Monitoring Board (DSMB) Approval to Complete Subject Enrollment in the Final Cohort of Phase III Study of TPOXX (tecovirimat); Company Submits Pivotal Animal Final Study Reports to FDA Actions
SIGA Announces Data Safety Monitoring Board (DSMB) Approval to Complete Subject Enrollment in the Final Cohort of Phase III Study of TPOXX (tecovirimat); Company Submits Pivotal Animal Final Study Reports to FDA Actions Achieve Critical BARDA Milestone; Company Now Eligible f
Read more →SIGAStephen Karotkin WEIL, GOTSHAL & MANGES LLP 767 Fifth Avenue New York, New York 10153 Telephone: (212)310-8000 Facsimile; (212) 310-8007 Attorneys for Reorganized Debtor UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT O
WEIL, GOTSHAL & MANGES LLP New York, New York 10153 Telephone: (212)310-8000 Facsimile; (212) 310-8007 Attorneys for Reorganized Debtor UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK x : In re : : Chapter 11 SIGA TECHNOLOGIES, INC., : : Case No. 14-12
Read more →SIGASIGA ANNOUNCES THAT DELAWARE SUPREME COURT AFFIRMS COURT OF CHANCERY OPINION NEW YORK - (BUSINESS WIRE) - SIGA Technologies, Inc. a company specializing in the commercialization of solutions for serious unmet medical nee
SIGA ANNOUNCES THAT DELAWARE SUPREME COURT AFFIRMS COURT OF CHANCERY OPINION NEW YORK - (BUSINESS WIRE) - SIGA Technologies, Inc. a company specializing in the commercialization of solutions for serious unmet medical needs and biothreats, today announced that the Delaware Suprem
Read more →SIGAUNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK x : In re : : Chapter 11 Case No. SIGA TECHNOLOGIES, INC., : : 14-12623 (SHL) Debtor. : : x DEBTOR'S CHAPTER 11 PLAN WEIL, GOTSHAL & MANGES LLP Stephen Karotki
UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK x : In re : : Chapter 11 Case No. SIGA TECHNOLOGIES, INC., : : 14-12623 (SHL) Debtor. : : x DEBTOR'S CHAPTER 11 PLAN WEIL, GOTSHAL & MANGES LLP Stephen Karotkin 767 Fifth Avenue New York, New York 1
Read more →SIGASIGA Technologies Receives NASDAQ Delisting Notification Delisting Follows Litigation Related Bankruptcy Filing NEW YORK, NY - SIGA Technologies, Inc. ("SIGA"), a company specializing in the development and commercializa
SIGA Technologies Receives NASDAQ Delisting Notification Delisting Follows Litigation Related Bankruptcy Filing NEW YORK, NY - SIGA Technologies, Inc. ("SIGA"), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biot
Read more →SIGASIGA TECHNOLOGIES, INC. APPEALS JUDGMENT OF DELAWARE COURT O F
SIGA TECHNOLOGIES, INC. APPEALS JUDGMENT OF DELAWARE COURT OF CHANCERY NEW YORK, January 16, 2015, (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company operating under the protection of the United States Bankruptcy Court for the Southern District of New York and
Read more →SIGADELAWARE
DELAWARE COURT DECISION REGARDING SIGA TECHNOLOGIES, INC. January 07, 2015 05:29 PM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (Nasdaq:SIGA), a company operating under the protection of the United States Bankruptcy Court for the Southern District o
Read more →SIGASIGA Technologies, Inc. Files for Chapter 11 Reorganization
SIGA Technologies, Inc. Files for Chapter 11 Reorganization NEW YORK, NY Sept. 16, 2014 -- SIGA Technologies, Inc. (NASDAQ:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced today that it
Read more →SIGASIGA Technologies Reports Financial Results for the Second Quarter 2014
NEW YORK, July 31, 2014 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today reported its financial results for the three and six months ended
Read more →SIGASIGA Technologies Reports Financial Results for the First Quarter 2014
NEW YORK, May 1, 2014 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today reported its financial results for the quarter ended March 31, 2014.
Read more →SIGASIGA Technologies Reports Financial Results for the Fourth Quarter and Year Ended 2013
NEW YORK, March 10, 2014 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today reported its financial results for the quarter and year ended Dec
Read more →SIGASIGA Technologies Reports Financial Results for the Third Quarter 2013
NEW YORK, Nov. 6, 2013 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA) today reported its financial results for the three and nine months ended September 30, 2013. Revenue for the three months ended September 30, 2013 was $2.3 million, matching the revenue level in the
Read more →SIGASIGA Technologies Reports Financial Results for the Second Quarter 2013
NEW YORK, Aug. 5, 2013 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA) today reported its financial results for the three and six months ended June 30, 2013. Revenue for the three months ended June 30, 2013 was $965,000, compared to $2.7 million in the second quarter o
Read more →SIGADelaware Supreme Court Reverses Equitable Payment Stream to PharmAthene and Remands Litigation to Trial Court for New Determination of Damages NEW YORK
Delaware Supreme Court Reverses Equitable Payment Stream to PharmAthene and Remands Litigation to Trial Court for New Determination of Damages NEW YORK, NEW YORK, May 26, 2013 - SIGA Technologies, Inc. (NASDAQ: SIGA) reported today that the Delaware Supreme Court reversed the a
Read more →SIGASIGA Technologies Reports Financial Results for the First Quarter 2013
NEW YORK, May 15, 2013 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapons, today reported its financial results for the quarter ended March 31, 2013. Revenu
Read more →SIGASIGA Delivers First Courses of Arestvyr(TM) Under BARDA Contract
SIGA Delivers First Courses of Arestvyr(TM) Under BARDA Contract NEW YORK, March 12, 2013 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapons, today announce
Read more →SIGASIGA Technologies Reports Financial Results for the Fourth Quarter and Year Ended 2012
NEW YORK, March 6, 2013 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapons, today reported its financial results for the quarter and year ended December 31,
Read more →SIGASIGA Technologies Reports Financial Results for the Third Quarter of 2012
NEW YORK, Nov. 5, 2012 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapons, today reported its financial results for the three and nine months ended September
Read more →SIGASIGA Technologies Reports Financial Results for the Second Quarter of 2012
NEW YORK, Aug. 6, 2012 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapons, today reported its financial results for the three and six months ended June 30, 2
Read more →SIGASIGA Appoints William J. Haynes as General Counsel New York, New York
SIGA Appoints William J. Haynes as General Counsel New York, New York, June 4, 2012 - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapons, announced today that it had appointed
Read more →SIGAChancery Court Issues Final Judgment In Litigation Brought By PharmAthene NEW YORK
Chancery Court Issues Final Judgment In Litigation Brought By PharmAthene NEW YORK, NEW YORK, June 1, 2012 (GLOBE NEWSWIRE) - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapo
Read more →SIGASIGA Technologies Reports Financial Results for the First Quarter 2012
NEW YORK, May 7, 2012 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapons, today reported its financial results for the quarter ended March 31, 2012. Revenue
Read more →SIGASIGA Technologies Reports Financial Results for the Fourth Quarter and Year Ended 2011
NEW YORK, New York, March 1, 2012 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapons, today reported its financial results for the fourth quarter and year en
Read more →SIGACHANCERY COURT DENIES MOTION FOR RECONSIDERATION IN PHARMATHENE LITIGATION; PROCEEDINGS CONTINUE New York, New York
CHANCERY COURT DENIES MOTION FOR RECONSIDERATION IN PHARMATHENE LITIGATION; PROCEEDINGS CONTINUE New York, New York, December 16, 2011 - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight lethal disease-causing pa
Read more →SIGASIGA Technologies Reports Financial Results for the Third Quarter of 2011
NEW YORK, Nov. 8, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biodefense pathogens, today reported its financial results for the three and nine months ended September 30, 2011. Revenu
Read more →SIGASIGA COMMENTS ON COURT RULING IN PHARMATHENE LITIGATION New York, New York
SIGA COMMENTS ON COURT RULING IN PHARMATHENE LITIGATION New York, New York, September 22, 2011 - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that the Delaware Court of C
Read more →SIGASIGA Technologies Reports Financial Results for the Second Quarter and First Half of 2011
NEW YORK, Aug. 1, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biodefense pathogens, today reported its financial results for the three and six months ended June 30, 2011. Revenue for
Read more →SIGASIGA TO SELL 1.7 MILLION COURSES OF ST-246 TO NATIONAL STOCKPILE UNDER MODIFIED BARDA CONTRACT GAO PROTEST WITHDRAWN New York, New York
SIGA TO SELL 1.7 MILLION COURSES OF ST-246 TO NATIONAL STOCKPILE UNDER MODIFIED BARDA CONTRACT GAO PROTEST WITHDRAWN New York, New York, June 27, 2011 - SIGA Technologies, Inc. (NASDAQ: SIGA) announced today that the Biomedical Advanced Research and Development Authority of th
Read more →SIGA, DATED MAY 13, 2011 exhibit99-1.htm SIGA TECHNOLOGIES AWARDED U.S. GOVERNMENT CONTRACT VALUED AT UP TO $2.8 BILLION New York
SIGA TECHNOLOGIES AWARDED U.S. GOVERNMENT CONTRACT VALUED AT New York, May 13, 2011 -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it has signed a contract with the
Read more →SIGASIGA Technologies Awarded U.S. Government Contract Valued at Up to $2.8 Billion
NEW YORK, May 13, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it has signed a contract with the Biomedical Advanced Research and Development
Read more →SIGASIGA Technologies Reports Financial Results for the First Quarter 2011
NEW YORK, May 5, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biodefense pathogens, today reported its financial results for the quarter ended March 31, 2011. Revenue for the three mon
Read more →SIGASIGA Technologies Reports Financial Results for the Fourth Quarter and Year Ended 2010
NEW YORK, March 9, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today reported its financial results for the fourth quarter and year ended December 31, 2010. Reve
Read more →SIGASIGA APPOINTS DANIEL LUCKSHIRE AS CHIEF FINANCIAL OFFICER New York, New York
SIGA APPOINTS DANIEL LUCKSHIRE AS CHIEF FINANCIAL OFFICER New York, New York, February 11, 2011 -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that it had appointed Da
Read more →SIGASIGA Technologies Reports Financial Results for the Third Quarter of 2010
NEW YORK, Nov. 2, 2010 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today reported its financial results for the third quarter and the nine months ended September 30, 2
Read more →SIGASIGA Technologies Reports Financial Results for the Second Quarter and First Half of 2010
NEW YORK, Aug. 5, 2010 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced its financial results for the second quarter and first half ended June 30, 2010. Fo
Read more →SIGASIGA Technologies Reports Operating Results for the First Quarter of 2010
NEW YORK, May 4, 2010 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of drugs to fight biowarfare pathogens, today reported its financial results for the quarter ended March 31, 2010. Total revenues for the quarter ended Marc
Read more →SIGASIGA Technologies Reports Financial Results for the Fourth Quarter and Full Year of 2009
NEW YORK, March 10, 2010 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced its financial results for the year ended December 31, 2009. For the full year 200
Read more →SIGASIGA Technologies, Inc. Announces Close of $20 Million Common Stock Offering
NEW YORK, Dec. 14, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced the closing of its offering of 2,725,339 shares of common stock to a select group o
Read more →SIGAModerator: This conference call contains or implies certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy
conference call contains or implies certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to marke
Read more →SIGASIGA Technologies, Inc. Raises $20.0 Million in a Common Stock Offering New York City
SIGA Technologies, Inc. Raises $20.0 in a Common Stock Offering New York City, December 10, 2009 -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it has entered i
Read more →SIGASIGA Technologies Reports Operating Results for the Third Quarter of 2009
NEW YORK, Nov. 9, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced its results of operations for the third quarter of 2009. The Company recognized rev
Read more →SIGASIGA Technologies to Discuss Third Quarter 2009 Results of Operations on November 9, 2009
NEW YORK, Nov. 2, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, plans to announce its third quarter 2009 results in a press release that will be issued on Monday N
Read more →SIGASIGA Technologies Files $100 Million Shelf Registration
NEW YORK, Oct. 30, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced the filing with the Securities and Exchange Commission (the "SEC") of a shelf registratio
Read more →SIGASIGA Technologies Inc. Approved for Nasdaq Global Market Listing New York, New York
SIGA Technologies Inc. Approved for Nasdaq Global Market Listing New York, New York, September 3, 2009 - SIGA Technologies Inc. (Nasdaq: SIGA) announced today that its common stock listing will transfer from the NASDAQ Capital Market to the NASDAQ Global Market. The transfer wil
Read more →SIGASIGA Technologies Receives a $3 Million Research Grant From the National Institutes of Health
NEW YORK, Sept. 2, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that it has received a Phase II grant of approximately $3 million from the Nationa
Read more →SIGASIGA Technologies Reports Operating Results for the Second Quarter of 2009
NEW YORK, Aug. 6, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced its results of operations for the second quarter of 2009. The Company recognized r
Read more →SIGASIGA Technologies Reschedules Quarterly Update Call to 10:30 AM EDT On August 6, 2009
NEW YORK, Aug. 3, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, has rescheduled its quarterly update call to 10:30 am EDT on Thursday, August 6, 2009 from 9:30 am
Read more →SIGASIGA Technologies to Announce Second Quarter 2009 Results of Operations On August 6, 2009
NEW YORK, July 27, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, plans to announce its second quarter 2009 results in a press release that will be issued on Thursd
Read more →SIGASIGA Technologies, Inc. to be Added to the Russell 3000(r) and Russell Global(r) Indices
NEW YORK, June 26, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it will be added to the Russell 3000(r) and the Russell Global(r) Indices, fol
Read more →SIGASIGA Technologies, Inc. to Present At the 2009 Noble Financial Fifth Annual Equity Conference
NEW YORK, June 5, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that Dr. Eric A. Rose, SIGA's Chief Executive Officer, will present at the 2009 Nobl
Read more →SIGASIGA Technologies Submits Response to BARDA RFP
NEW YORK, May 14, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of drugs to fight biowarfare pathogens, today announced that on May 11, 2009, it submitted its response to the Biomedical Advance Research and Development A
Read more →SIGASIGA Technologies to Announce First Quarter 2009 Results of Operations On May 14, 2009
NEW YORK, May 8, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, plans to announce its first quarter 2009 results in a press release that will be issued on Thursday,
Read more →SIGASIGA Technologies to Discuss Year-End 2008 Results of Operations On March 12, 2009
NEW YORK, March 9, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, plans to discuss its year-end 2008 results in a press release that will be issued on Thursday, Mar
Read more →SIGASIGA Technologies Completes Human Pharmacokinetic Bridging Study Validating Commercial Formulation
NEW YORK, Dec. 2, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced the completion of a Phase I investigational tria
Read more →SIGASIGA Technologies Reports Operating Results for the Third Quarter of 2008
NEW YORK, Nov. 10, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced its results of operations for the third quarter of 2008. The Company recognized re
Read more →SIGASIGA Technologies to Present At the Rodman and Renshaw Annual Global Investment Conference
NEW YORK, Nov. 6, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that the Company's CEO, Dr. Eric A. Rose, will be presenting at the Rodman and Rensh
Read more →SIGASIGA Technologies to Announce Third Quarter 2008 Results of Operations On November 10, 2008
NEW YORK, Oct. 31, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, plans to announce its third quarter 2008 results in a press release that will be issued on Monday,
Read more →SIGASIGA Technologies Named to Deloitte Tri-State Area Technology Fast 50
NEW YORK, Oct. 23, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that it has been selected as a winner of the Deloitte New York, New Jersey, Connec
Read more →SIGASIGA Technologies' ST-246 Named 'Molecule of the Month' by Prous Science
NEW YORK, Oct. 15, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that Prous Science, a division of Thomson Reuters, has recognized ST-246, SIGA's s
Read more →SIGASIGA Technologies to Participate in Committee Meeting for the Institute of Medicine
NEW YORK, Sept. 25, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that Dr. Dennis E. Hruby, Chief Scientific Officer, will be participating as an outside
Read more →SIGASIGA Technologies to Attend the HHS Public Health Emergency Medical Countermeasures Enterprise Stakeholders Workshop 2008 and BARDA Industry Day
NEW YORK, Sept. 18, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and emerging human health threats, today announced that Dr. Dennis Hruby, SIGA's Chief Scientific O
Read more →SIGASIGA Technologies Receives Additional $20 Million from NIH for ST-246 Antiviral Therapeutic Development New York, New York
Technologies Receives Additional $20 Million from NIH for Antiviral Therapeutic Development September 18, 2008 - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that it
Read more →SIGASIGA Technologies Awarded $55 Million by Federal Government to Develop Broader Applications for its Lead Drug Candidate ST-246 New York, New York
Technologies Awarded $55 Million by Federal Government to Broader Applications for its Lead Drug Candidate ST-246 September 3, 2008 - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, tod
Read more →SIGASIGA Technologies Reports Operating Results for the Second Quarter of 2008
NEW YORK, Aug. 12, 2008 (PRIME NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced its results of operations for the second quarter of 2008. The Company recognized r
Read more →SIGASIGA Technologies to Announce Second Quarter 2008 Results of Operations on August 12, 2008
NEW YORK, Aug. 5, 2008 (PRIME NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, plans to announce its second quarter 2008 results in a press release that will be issued on Tuesday
Read more →SIGAFINAL SIGA Technologies, Inc. Investor Update Conference Call Tuesday
Update Conference Call you, Eric. Good morning everyone and welcome to the first investor update conference call hosted by SIGA Technologies. We expect this to be the initiation of a series of conference calls that the Company will host conjunction with its quarterly and annu
Read more →SIGASIGA'S SMALLPOX DRUG CANDIDATE ADMINISTERED TO CRITICALLY ILL HUMAN PATIENT New York
SMALLPOX DRUG CANDIDATE TO CRITICALLY ILL HUMAN PATIENT SIGA) announced today that a toddler who inadvertently contracted eczema vaccinatum has been treated with ST-246, SIGA's lead smallpox drug candidate, pursuant to an Emergency Investigational New Drug Application (IND) g
Read more →SIGATom Konatich SIGA Technologies, Inc. Chief Financial Officer & Acting CEO (212) 672-9100 SIGA APPOINTS DR. ERIC A. ROSE CHAIRMAN OF THE BOARD, WILL BECOME CEO ON MARCH 1, 2007 New York
Financial Officer & Acting CEO APPOINTS DR. ERIC A. ROSE CHAIRMAN OF THE BOARD, WILL SIGA) announced today that Eric A. Rose, M.D. was elected Chairman of the Company's Board of Directors at a meeting of the Board on January 25, 2007. On March 1, 2007, Dr. Rose will be taking
Read more →SIGATom Konatich SIGA Technologies, Inc. Chief Financial Officer & Acting CEO (212) 672-9100 FDA APPROVES ORPHAN DRUG DESIGNATION FOR SIGA'S SMALLPOX DRUG, SIGA-246 THE DESIGNATION IS FOR BOTH TREATMENT AND PREVENTI
Financial Officer & Acting CEO APPROVES ORPHAN DRUG DESIGNATION FOR SMALLPOX DRUG, SIGA-246 DESIGNATION IS FOR BOTH TREATMENT AND PREVENTION OF December 20, 2006 -- SIGA SIGA) announced today that the Office of Orphan Products Development (OOPD) the United States Food and D
Read more →SIGATom Konatich SIGA Technologies, Inc. Chief Financial Officer & Acting CEO (212) 672-9100 SIGA ANNOUNCES $9.0 MILLION PRIVATE PLACEMENT New York, NY
Financial Officer & Acting CEO ANNOUNCES $9.0 MILLION PRIVATE PLACEMENT NY, October 19, 2006 -- SIGA SIGA) announced today that on October 18, 2006 it entered into a Securities Purchase Agreement for the issuance and sale to institutional investors of 2,000,000 shares of the
Read more →SIGADebbie Raskin Rubenstein Associates, Inc. (212) 843-8028 draskin@rubenstein.com SIGA ANNOUNCES SMALLPOX TREATMENT BREAKTHROUGH SIGA DRUG COMPLETELY PREVENTS SMALLPOX DISEASE IN PRELIMINARY PRIMATE TRIAL New York
draskin@rubenstein.com ANNOUNCES SMALLPOX TREATMENT BREAKTHROUGH DRUG COMPLETELY PREVENTS SMALLPOX DISEASE PRELIMINARY PRIMATE TRIAL NY, October 18, 2006 -- SIGA SIGA) announced today that its lead drug, SIGA-246, is the first drug ever demonstrate 100% protection against h
Read more →SIGAThomas N. Konatich SIGA Technologies, Inc. Chief Financial Officer & Acting CEO (212) 672-9100 SIGA RECEIVES $16.5 MILLION FROM THE NIH TO ADVANCE DEVELOPMENT OF ITS SMALLPOX DRUG CANDIDATE, SIGA-246 Total Fundi
RECEIVES $16.5 MILLION FROM THE NIH TO ADVANCE OF ITS SMALLPOX DRUG CANDIDATE, SIGA-246 Funding Awards Received by SIGA Since August 2, 2006 Now Exceeds $27 October 4, 2006-- SIGA Technologies, Inc. (NASDAQ: SIGA) today announced the receipt of a 3 year, $16.5 million contrac
Read more →SIGAMr. Thomas Konatich Chief Financial Officer and Acting Chief Executive Officer SIGA Technologies, Inc. (212) 672-9100 SIGA REPORTS ON CORRESPONDENCE FROM NASDAQ New York
Financial Officer and Chief Executive Officer REPORTS ON CORRESPONDENCE FROM NASDAQ August 28, 2006-- SIGA Technologies, Inc. (NASDAQ: SIGA) disclosed today that August 22, 2006, it received a staff determination letter from the Nasdaq Stock Market ("Nasdaq") indicating that
Read more →SIGAFor PharmAthene, Inc . : Stacey Jurchison Phone: 410-571-8925 jurchisons@pharmathene.com For SIGA Technologies, Inc . : Thomas N. Konatich Phone: 212-672-9100 tkonatich@siga.com PHARMATHENE AND SIGA TECHNOLOGIES
AND SIGA TECHNOLOGIES SIGN DEFINITIVE MERGER TO ESTABLISH PREMIER BIODEFENSE COMPANY MD and NEW YORK, NY, June 9, 2006 PharmAthene, Inc. and SIGA Technologies, Inc. (NASDAQ: SIGA) announced today that they have signed a definitive agreement providing for the merger of PharmA
Read more →SIGAThomas N. Konatich SIGA Technologies, Inc. Chief Financial Officer (212) 672-9100 SIGA REPORTS RESIGNATION OF CHIEF EXECUTIVE OFFICER New York
REPORTS RESIGNATION OF CHIEF EXECUTIVE OFFICER April 3, 2006 - In anticipation of the closing of the proposed merger with Pharmathene, Inc., announced March 14, 2006, SIGA SIGA) and Dr. Bernard L. Kasten, its Chief Executive Officer, announced Dr. Kasten's agreement to resign
Read more →SIGAFor SIGA Technologies, Inc. : Thomas N. Konatich Phone: 212-672-9100 tkonatich@siga.com For PharmAthene, Inc. : Stacey Jurchison Phone: 410-571-8925 Cell: 410-474-8200 jurchisons@pharmathene.com PHARMATHENE AND
AND SIGA TECHNOLOGIES ANNOUNCE PLANS TO MERGE TO ESTABLISH PREMIER BIODEFENSE MD and NEW YORK, NY, March 14, 2006 PharmAthene, Inc. and SIGA Technologies, Inc. (NASDAQ: SIGA) announced today that they have entered into a term sheet providing for the merger of PharmAthene and
Read more →SIGADr. Bernard Kasten SIGA Technologies, Inc. Chief Executive Officer (212) 672-9100 SIGA REPORTS ON CORRESPONDENCE FROM NASDAQ New York
REPORTS ON CORRESPONDENCE FROM NASDAQ February 3, 2006 -- SIGA SIGA) disclosed today that on January 31, 2006, it received notice from the Nasdaq Stock Market ("NASDAQ") that for the past 30 consecutive business days, the bid price of the SIGA's common stock has closed below
Read more →SIGASiGA[LOGO] Contact: Dr. Bernard Kasten SIGA Technologies, Inc. Chief Executive Officer (212) 672-9100 FDA APPROVES SIGA'S INVESTIGATIONAL NEW DRUG APPLICATION FOR ITS SMALLPOX DRUG SIGA-246 New York
SIGA Technologies, Inc. Chief Executive Officer FDA APPROVES SIGA'S INVESTIGATIONAL NEW DRUG APPLICATION FOR ITS SMALLPOX DRUG SIGA-246 New York, December 13, 2005 -- SIGA Technologies, Inc. (NASDAQ: SIGA) announced today that the U.S. Food and Drug Administration (FDA) acce
Read more →SIGASIGA Contact: Dr. Bernard L. Kasten SIGA Technologies, Inc. CEO bkasten@siga.com (212) 672-9100 SIGA ANNOUNCES A $2.0 MILLION PRIVATE PLACEMENT New York
Dr. Bernard L. Kasten SIGA Technologies, Inc. SIGA ANNOUNCES A $2.0 MILLION PRIVATE PLACEMENT New York, November 3, 2005 -- SIGA Technologies, Inc. (NASDAQ: SIGA) today announced that on November 2, 2005, the company entered into a Securities Purchase Agreement for the issua
Read more →SIGASIGA Contact: Dr. Bernard L. Kasten SIGA Technologies, Inc. CEO bkasten@siga.com (212) 672-9100 SIGA ANNOUNCES SUCCESS OF ITS SMALLPOX COMPOUND IN A MONKEYPOX MODEL New York
Dr. Bernard L. Kasten SIGA Technologies, Inc. SIGA ANNOUNCES SUCCESS OF ITS SMALLPOX COMPOUND IN A MONKEYPOX MODEL New York, October 6, 2005 -- SIGA Technologies, Inc. (NASDAQ: SIGA) today announced that the company's lead smallpox compound, SIGA-246, completely protected g
Read more →SIGASIGA Contact: Dr. Bernard L. Kasten SIGA Technologies, Inc. CEO bkasten@siga.com (212) 672-9100 SIGA TECHNOLOGIES RECEIVES LETTERS FROM NASDAQ New York
Dr. Bernard L. Kasten SIGA Technologies, Inc. SIGA TECHNOLOGIES RECEIVES LETTERS FROM NASDAQ New York, September 28, 2005 -- SIGA Technologies, Inc. (NASDAQ: SIGA) announced today that on September 22, 2005, it received notice from the Nasdaq Stock Market ("NASDAQ") that for
Read more →SIGASIGA Contact: Investor Contact: Dr. Bernard Kasten Dianne Will SIGA Technologies, Inc. Willstar Consultants, Inc. CEO (518) 398-6222 (212) 672-9100 dwill@willstar.net ------------------ SIGA AND TRANSTECH PHARMA ANNOUNCE
Contact: Investor Contact: Dr. Bernard Kasten Dianne Will SIGA Technologies, Inc. Willstar Consultants, Inc. (212) 672-9100 dwill@willstar.net SIGA AND TRANSTECH PHARMA ANNOUNCE RECEIPT OF $2.7 MILLION IN NIH FUNDING New York, NY. and Greensboro, NC., February 15, 2005 - Sci
Read more →SIGASIGA Contact: Investor Contact: Dr. Bernard Kasten Dianne Will SIGA Technologies, Inc. Willstar Consultants, Inc. Chief Executive Officer (518) 398-6222 (212) 672-9100 dwill@willstar.net ------------------ SIGA Technolog
Contact: Investor Contact: Dr. Bernard Kasten Dianne Will SIGA Technologies, Inc. Willstar Consultants, Inc. Chief Executive Officer (518) 398-6222 (212) 672-9100 dwill@willstar.net SIGA Technologies To Present at The Wall Street Analyst Forum in New York City on November 3
Read more →SIGASIGA Contact: Investor Contact: Dr. Bernard Kasten Dianne Will SIGA Technologies, Inc. Willstar Consultants, Inc. Chief Executive Officer (518) 398-6222 (212) 672-9100 dwill@willstar.net -------------------------- SIGA T
Contact: Investor Contact: Dr. Bernard Kasten Dianne Will SIGA Technologies, Inc. Willstar Consultants, Inc. Chief Executive Officer (518) 398-6222 (212) 672-9100 dwill@willstar.net -------------------------- SIGA TECHNOLOGIES TO PRESENT AT THE NEW YORK SOCIETY OF SECURITY
Read more →SIGASIGA Contact: Investor Contact: Dr. Bernard Kasten Dianne Will SIGA Technologies, Inc. Willstar Consultants, Inc. Chief Executive Officer (518) 398-6222 (212) 672-9100 dwill@willstar.net ------------------ SIGA TECHNOLOG
Contact: Investor Contact: Dr. Bernard Kasten Dianne Will SIGA Technologies, Inc. Willstar Consultants, Inc. Chief Executive Officer (518) 398-6222 (212) 672-9100 dwill@willstar.net SIGA TECHNOLOGIES TO PRESENT AT THE RODMAN & RENSHAW TECHVEST 6TH ANNUAL HEALTHCARE CONFEREN
Read more →SIGAInvestor Contact: Dr. Bernard Kasten Dianne Will SIGA Technologies, Inc. Willstar Consultants, Inc. Chief Executive Officer (518) 398-6222 (212) 672-9100 dwill@willstar.net SIGA announces SUCCESS of its Smallpox
Contact: Investor Contact: Dr. Bernard Kasten Dianne Will SIGA Technologies, Inc. Willstar Consultants, Inc. Chief Executive Officer (518) 398-6222 SIGA announces SUCCESS of its Smallpox Compound in Mice New York, October 5, 2004 -- SIGA Technologies, Inc. (NASDAQ: SIGA) tod
Read more →SIGAInvestor Contact: Thomas N. Konatich Dianne Will Chief Financial Officer Willstar Consultants, Inc. SIGA Technologies, Inc. (518) 398-6222 (212) 672-9100 dwill@willstar.net SIGA secures $4 Million in government
Contact: Investor Contact: Thomas N. Konatich Dianne Will Chief Financial Officer Willstar Consultants, Inc. SIGA Technologies, Inc. (518) 398-6222 (212) 672-9100 dwill@willstar.net SIGA secures $4 Million in government funding for defense research New York, September 14, 2
Read more →SIGAInvestor Contact: Thomas N. Konatich Dianne Will Chief Financial Officer Willstar Consultants, Inc. SIGA Technologies, Inc. (518) 398-6222 (212) 672-9100 dwill@willstar.net ------------------ SIGA announces Rece
Contact: Investor Contact: Thomas N. Konatich Dianne Will Chief Financial Officer Willstar Consultants, Inc. SIGA Technologies, Inc. (518) 398-6222 (212) 672-9100 dwill@willstar.net SIGA announces Receipt of $12 Million in nih funding FOR bIODEFENsE New York, August 25, 200
Read more →Competitive Position
How SIGA ranks across every disease it competes inCompetitive Position is a premium feature
See how SIGA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial